Publication

Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia

Cheng, Z., Dai, Y., Pang, Y., Jiao, Y., Liu, Y., Cui, L., Quan, L., Qian, T., Zeng, T., Si, C., Huang, W., Chen, J., Pang, Y., Ye, X., Shi, J. & Fu, L., 21-Nov-2019, In : Journal of cellular and molecular medicine. 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Cheng, Z., Dai, Y., Pang, Y., Jiao, Y., Liu, Y., Cui, L., ... Fu, L. (2019). Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia. Journal of cellular and molecular medicine. https://doi.org/10.1111/jcmm.14831

Author

Cheng, Zhiheng ; Dai, Yifeng ; Pang, Yifan ; Jiao, Yang ; Liu, Yan ; Cui, Longzhen ; Quan, Liang ; Qian, Tingting ; Zeng, Tiansheng ; Si, Chaozeng ; Huang, Wenhui ; Chen, Jinghong ; Pang, Ying ; Ye, Xu ; Shi, Jinlong ; Fu, Lin. / Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia. In: Journal of cellular and molecular medicine. 2019.

Harvard

Cheng, Z, Dai, Y, Pang, Y, Jiao, Y, Liu, Y, Cui, L, Quan, L, Qian, T, Zeng, T, Si, C, Huang, W, Chen, J, Pang, Y, Ye, X, Shi, J & Fu, L 2019, 'Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia', Journal of cellular and molecular medicine. https://doi.org/10.1111/jcmm.14831

Standard

Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia. / Cheng, Zhiheng; Dai, Yifeng; Pang, Yifan; Jiao, Yang; Liu, Yan; Cui, Longzhen; Quan, Liang; Qian, Tingting; Zeng, Tiansheng; Si, Chaozeng; Huang, Wenhui; Chen, Jinghong; Pang, Ying; Ye, Xu; Shi, Jinlong; Fu, Lin.

In: Journal of cellular and molecular medicine, 21.11.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Cheng Z, Dai Y, Pang Y, Jiao Y, Liu Y, Cui L et al. Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia. Journal of cellular and molecular medicine. 2019 Nov 21. https://doi.org/10.1111/jcmm.14831


BibTeX

@article{87e8cb3356fa425cb2436f9a49bf8082,
title = "Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia",
abstract = "The mammalian target of rapamycin (mTOR) inhibitor, DNA damage inducible transcript 4 (DDIT4), has inducible expression in response to various cellular stresses. In multiple malignancies, studies have shown that DDIT4 participates in tumorigenesis and impacts patient survival. We aimed to study the prognostic value of DDIT4 in acute myeloid leukaemia (AML), which is currently unclear. Firstly, The Cancer Genome Atlas was screened for AML patients with complete clinical characteristics and DDIT4 expression data. A total of 155 patients were included and stratified according to the treatment modality and the median DDIT4 expression levels. High DDIT4 expressers had shorter overall survival (OS) and event-free survival (EFS) than the low expressers among the chemotherapy-only group (all P <.001); EFS and OS were similar in the high and low DDIT4 expressers of the allogeneic haematopoietic stem cell transplantation (allo-HSCT) group. Furthermore, in the DDIT4(high) group, patients treated with allo-HSCT had longer EFS and OS than those who received chemotherapy alone (all P <.01). In the DDIT4(low) group, OS and EFS were similar in different treatment groups. Secondly, we analysed two other cytogenetically normal AML (CN-AML) cohorts derived from the Gene Expression Omnibus database, which confirmed that high DDIT4 expression was associated with poorer survival. Gene Ontology (GO) enrichment analysis showed that the genes related to DDIT4 expression were mainly concentrated in the acute and chronic myeloid leukaemia signalling pathways. Collectively, our study indicates that high DDIT4 expression may serve as a poor prognostic factor for AML, but its prognostic effects could be outweighed by allo-HSCT.",
keywords = "acute myeloid leukaemia, allogeneic haematopoietic stem cell transplantation, chemotherapy, DNA damage inducible transcript 4, prognosis, REDD1, CANCER, EXPRESSION, DIAGNOSIS, ADULTS, CELLS",
author = "Zhiheng Cheng and Yifeng Dai and Yifan Pang and Yang Jiao and Yan Liu and Longzhen Cui and Liang Quan and Tingting Qian and Tiansheng Zeng and Chaozeng Si and Wenhui Huang and Jinghong Chen and Ying Pang and Xu Ye and Jinlong Shi and Lin Fu",
year = "2019",
month = "11",
day = "21",
doi = "10.1111/jcmm.14831",
language = "English",
journal = "Journal of cellular and molecular medicine",
issn = "1582-1838",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia

AU - Cheng, Zhiheng

AU - Dai, Yifeng

AU - Pang, Yifan

AU - Jiao, Yang

AU - Liu, Yan

AU - Cui, Longzhen

AU - Quan, Liang

AU - Qian, Tingting

AU - Zeng, Tiansheng

AU - Si, Chaozeng

AU - Huang, Wenhui

AU - Chen, Jinghong

AU - Pang, Ying

AU - Ye, Xu

AU - Shi, Jinlong

AU - Fu, Lin

PY - 2019/11/21

Y1 - 2019/11/21

N2 - The mammalian target of rapamycin (mTOR) inhibitor, DNA damage inducible transcript 4 (DDIT4), has inducible expression in response to various cellular stresses. In multiple malignancies, studies have shown that DDIT4 participates in tumorigenesis and impacts patient survival. We aimed to study the prognostic value of DDIT4 in acute myeloid leukaemia (AML), which is currently unclear. Firstly, The Cancer Genome Atlas was screened for AML patients with complete clinical characteristics and DDIT4 expression data. A total of 155 patients were included and stratified according to the treatment modality and the median DDIT4 expression levels. High DDIT4 expressers had shorter overall survival (OS) and event-free survival (EFS) than the low expressers among the chemotherapy-only group (all P <.001); EFS and OS were similar in the high and low DDIT4 expressers of the allogeneic haematopoietic stem cell transplantation (allo-HSCT) group. Furthermore, in the DDIT4(high) group, patients treated with allo-HSCT had longer EFS and OS than those who received chemotherapy alone (all P <.01). In the DDIT4(low) group, OS and EFS were similar in different treatment groups. Secondly, we analysed two other cytogenetically normal AML (CN-AML) cohorts derived from the Gene Expression Omnibus database, which confirmed that high DDIT4 expression was associated with poorer survival. Gene Ontology (GO) enrichment analysis showed that the genes related to DDIT4 expression were mainly concentrated in the acute and chronic myeloid leukaemia signalling pathways. Collectively, our study indicates that high DDIT4 expression may serve as a poor prognostic factor for AML, but its prognostic effects could be outweighed by allo-HSCT.

AB - The mammalian target of rapamycin (mTOR) inhibitor, DNA damage inducible transcript 4 (DDIT4), has inducible expression in response to various cellular stresses. In multiple malignancies, studies have shown that DDIT4 participates in tumorigenesis and impacts patient survival. We aimed to study the prognostic value of DDIT4 in acute myeloid leukaemia (AML), which is currently unclear. Firstly, The Cancer Genome Atlas was screened for AML patients with complete clinical characteristics and DDIT4 expression data. A total of 155 patients were included and stratified according to the treatment modality and the median DDIT4 expression levels. High DDIT4 expressers had shorter overall survival (OS) and event-free survival (EFS) than the low expressers among the chemotherapy-only group (all P <.001); EFS and OS were similar in the high and low DDIT4 expressers of the allogeneic haematopoietic stem cell transplantation (allo-HSCT) group. Furthermore, in the DDIT4(high) group, patients treated with allo-HSCT had longer EFS and OS than those who received chemotherapy alone (all P <.01). In the DDIT4(low) group, OS and EFS were similar in different treatment groups. Secondly, we analysed two other cytogenetically normal AML (CN-AML) cohorts derived from the Gene Expression Omnibus database, which confirmed that high DDIT4 expression was associated with poorer survival. Gene Ontology (GO) enrichment analysis showed that the genes related to DDIT4 expression were mainly concentrated in the acute and chronic myeloid leukaemia signalling pathways. Collectively, our study indicates that high DDIT4 expression may serve as a poor prognostic factor for AML, but its prognostic effects could be outweighed by allo-HSCT.

KW - acute myeloid leukaemia

KW - allogeneic haematopoietic stem cell transplantation

KW - chemotherapy

KW - DNA damage inducible transcript 4

KW - prognosis

KW - REDD1

KW - CANCER

KW - EXPRESSION

KW - DIAGNOSIS

KW - ADULTS

KW - CELLS

U2 - 10.1111/jcmm.14831

DO - 10.1111/jcmm.14831

M3 - Article

JO - Journal of cellular and molecular medicine

JF - Journal of cellular and molecular medicine

SN - 1582-1838

ER -

ID: 107583909